Introduction
============

Hereditary retinal degeneration (HRD) is a clinically and genetically heterogeneous group of diseases that cause visual loss due to progressive loss of rod and/or cone photoreceptor cells in the retina. In cone-rod dystrophy (CRD), cone involvement initially exceeds that of rods, and therefore the predominant symptoms are reduced visual acuity, photophobia, defective color vision, and decreased sensitivity in the central visual field, later followed by progressive loss in peripheral vision and night blindness. Additional ophthalmologic findings include pigment deposits visible on fundus examination, predominantly localized to the macular region. The prevalence of CRD is approximately 1/40,000 \[[@r1],[@r2]\].

CRD is a heterogeneous disorder. In most patients, the disease is limited to the eye (nonsyndromic), with no extraocular manifestations. Nonsyndromic CRD can be inherited as autosomal recessive (ar), autosomal dominant (ad), or X-linked (XL). More than 20 genes and loci have been implicated in nonsyndromic CRD, of which at least six are associated with an autosomal recessive mode of inheritance (Retnet- Retinal Information Network, [RetNet](http://www.sph.uth.tmc.edu/Retnet/)). One is *CDHR1.*

*CDHR1* (previously known as *PCDH21*) encodes for cadherin-related family member 1. Members of the cadherin family of transmembrane proteins are often involved in calcium-dependent cell adhesion. Cadherins are characterized by the presence of 1--34 extracellular cadherin (EC) domains (composed of about 110 amino acids), which contain highly conserved Ca^2+^-binding motifs. Variations in the cytoplasmic domains impart functional specificity by conferring to each molecule the ability to interact with different ligands (reviewed in \[[@r3]\]). Interestingly, four members of the cadherin family have been linked to retinal degeneration: Mutations in the genes encoding cadherin 23 (*CDH23*) and protocadherin 15 (*PCDH15*) cause Usher syndrome (a syndromic form of HRD, characterized by the combination of retinitis pigmentosa \[RP\] and hearing loss) \[[@r4]--[@r6]\], mutations of *CDH3*, encoding P-cadherin, lead to hypotrichosis with juvenile macular dystrophy \[[@r7]\], and mutations of *CDHR1* cause arCRD \[[@r8]\].

*CDHR1* consists of six EC domains with a unique intracellular domain. *CDHR1* is expressed only in a small subset of neuronal tissues, including the olfactory bulb and the retina \[[@r9],[@r10]\]. In the retina, *CDHR1* is localized to the junction between the inner and outer segments of rod and cone photoreceptors, and has a crucial role in photoreceptor outer segment disc assembly. Outer segments of *CDHR1* knockout mice are disorganized, and there is progressive death of photoreceptor cells \[[@r10]\]. *CDHR1* was therefore an obvious candidate for human retinal degeneration. Screening of the *CDHR1* gene in a large cohort of patients with various forms of HRD led to the identification of two missense variants: p.A212T and p.P532A. Both variants affected evolutionary conserved residues, and were not detected in unaffected controls. However, since both were found in a heterozygous state and a second allele could not be identified in both cases, their pathogenicity remained uncertain \[[@r11]\]. Recently, three distinct pathogenic mutations of *CDHR1* have been reported in patients with CRD from the Faroe Islands, the Middle East, and South Asia \[[@r8],[@r12]\] ([Table 1](#t1){ref-type="table"}). Here we report a novel splice site mutation of *CDHR1* underlying arCRD in a consanguineous Israeli Christian Arab family.

###### Currently known pathogenic mutations of the CDHR1 gene

  Exon/Intron   Base change    Amino acid substitution   Ethnicity                Reference
  ------------- -------------- ------------------------- ------------------------ ----------------
  Exon 4        c.338delG      p.G113AfsX1               Middle East              \[[@r12]\]
  Exon 6        c.524dupA      p.Q175QfsX47              Faroe Islands            \[[@r8]\]
  Exon 13       c.1459delG     p.G487GfsX20              South Asia               \[[@r12]\]
  Intron 13     c.1485+2T\>G   Aberrant splicing         Israeli Christian Arab   Current report

Methods
=======

Patients
--------

Four members of a Christian Arab consanguineous family from northern Israel (family TB127) were ascertained for this study. The study was performed in accordance with the Declaration of Helsinki, and written informed consent was obtained from all participants. The research was approved by the local institutional review board at Ha'emek Medical Center and by the National Helsinki Committee for Genetic Research in Humans. DNA control samples were obtained from Christian Arab individuals from northern Israel who presented for routine genetic testing and consented for the use of their DNA samples in additional genetic studies.

DNA analysis
------------

Venous blood samples were obtained using K3EDTA vacuette tubes (Greiner Bio-One, Kremsmunster, Austria), and genomic DNA was extracted using a high salt solution according to a standard protocol \[[@r13]\]. Genome-wide homozygosity mapping was performed using the HumanCytoSNP-12v2.1 BeadChip (220 K; Illumina, Inc., San Diego, CA). Homozygous regions were calculated using HomozygosityMapper \[[@r14]\]. For mutation analysis, specific primers were used to PCR-amplify the 17 exons of *CDHR1*, including intron-exon boundaries. Primer sequences were as previously described \[[@r8],[@r11]\]. Mutation screening was performed by direct sequencing with the Big Dye terminator cycle sequencing kit on an ABI 3130×l Genetic Analyzer (PE Applied Biosystems, Foster City, CA). The DNA control samples for the c.1485+2T\>G mutation were screened with a restriction endonuclease-based assay with HpyCH4III (New England Biolabs, Beverly, MA). *CDHR1* exon 13 was PCR-amplified in a 25 μl reaction volume. Twenty μl of the products were digested overnight in a 30 μl volume with HpyCH4III (5 U, 37 °C) and 1X of the recommended buffer. The entire reaction volume (30 μl) was visualized with electrophoresis on a 2% agarose gel. Expected band sizes were 300 and 90 bp for the wild-type allele and 390 bp for the mutant allele.

Splice site score predictions
-----------------------------

The genomic sequence environment of the mutation was analyzed for 5′ and 3′ splice sites using [Automated Splice Site Analyses](https://splice.uwo.ca/) \[[@r15]\] and ASD -- [Intron Analysis](http://www.ebi.ac.uk/asd-srv/wb.cgi?method=6) \[[@r16]\].

Results
=======

Clinical findings
-----------------

Family TB127 is a Christian Arab family from northern Israel. Parents are first cousins, and two of their five offspring have CRD ([Figure 1A](#f1){ref-type="fig"}). Impaired day vision was first noticed in their 20s. In the third decade of life, electroretinographic (ERG) cone response was absent, while rod response was markedly reduced ([Table 2](#t2){ref-type="table"}). Pattern visual evoked potentials were of reduced waveforms and prolonged implicit time, indicating severely reduced macular function. Flash visual evoked potentials indicated that nerve conduction of both optic nerves to the visual cortex was within normal limits (data not shown). In the fourth decade of life, visual acuity was markedly decreased, and color vision was severely impaired ([Table 2](#t2){ref-type="table"}). Humphrey visual field testing showed bilateral deep large central scotomas with significant general reduction of sensitivity in both eyes. Optical coherence tomography imaging showed bilateral severe thinning of the macula. For example, in patient IV:3 macular thickness in the right eye was 140 μm (normal 200 μm), and there was loss of the foveal contour. In the left eye, the macular thickness was normal, but loss of the foveal contour was more prominent than in the right eye ([Figure 2A](#f2){ref-type="fig"}). An irregular retinal pigment epithelium layer was seen in optical coherence tomography of one patient (individual IV:2; [Figure 2B](#f2){ref-type="fig"}). Funduscopic examination revealed pink optic discs and moderately attenuated retinal vessels. Macular involvement was indicated by the lack of macular reflex, and by macular atrophy. In patient IV:2, there were no pigmentary changes, while in patient IV:3 pigmentary changes (beaten bronze like) were observed in the macula, and in the periphery there were a few bone spicule-like pigmentation deposits and punctate salt- and pepper-like appearance ([Figure 2C,D](#f2){ref-type="fig"}).

![Pedigree and mutation analysis. **A**: Shown is a consanguineous Israeli Christian Arab family segregating arCRD (family TB127). Filled symbols represent affected individuals, whereas clear symbols represent unaffected individuals. Genotypes of family members at the *CDHR1* gene are indicated. m, mutant allele; +, wt allele. **B**: Nucleotide sequence traces of the boundary between the *CDHR1* exon and Intron 13 in a non-carrier individual (wt) and an affected individual homozygote for the c.1485+2T\>**G**: mutant allele (mut). The exon-intron boundary is marked.](mv-v18-2915-f1){#f1}

###### Clinical characteristics of individuals homozygous for the CDHR1 c.1485+2T\>G mutation

  Patient No. Sex   Age (y)   Visual acuity   Refractive error   Color vision (Ishihara)   FFERG\*                  
  ----------------- --------- --------------- ------------------ ------------------------- --------- ---- ---- ---- ------------
  IV-2 F            36        6/120(OU)       OD −11             1st panel not seen (OU)   23        OD   NR   ND   a 0 b 80 †
  OS −13            OS        NR              ND                 a 0 b 50                                           
  IV-3 F            38        6/120(OU)       ND                 1st panel not seen (OU)   30        OD   NR   NR   a 0 b 17 ‡
  OS                ND        ND              ND                                                                    

F, Female; y, years; OD, right eye; OS, left eye; OU, both eyes; NR, Non-Recordable; ND, Not Determined \*Full-Field Electroretinogram; LA: light adaptation (cone ERG); DA: dark adaptation (rod ERG) ║ERG recordings for the two patients were performed with different systems. Therefore, the normal range is indicated for each patient separately. †DA: Normal a-wave 260--630μV; Normal b-wave 440--800 μV ‡DA: Normal a-wave 160--320 μV; Normal b-wave 300--500 μV

![Optical coherence tomography and fundus photographs of affected individuals. **A**: Optical coherence tomography (OCT) of the right eye of individual IV:3 at the age of 38 years shows macular thinning and loss of foveal contour. **B**: OCT of the right eye of individual IV:2 at the age of 36 years shows severe thinning of the macula, with irregular retinal pigment epithelium (RPE). **C**: Fundus photograph of individual IV:3 at the age of 38 years demonstrating pink optic disc and moderately attenuated retinal vessels. Macular involvement is indicated by the lack of macular reflex, and by macular atrophy. Pigmentary changes (beaten bronze like) are observed in the macular region. **D**: Fundus photograph of retinal periphery in individual IV:3 demonstrating bone spicule-like pigmentation deposits and punctate salt- and pepper-like appearance.](mv-v18-2915-f2){#f2}

Genetic analysis
----------------

Family TB127 is consanguineous, and CRD segregates in an autosomal recessive mode. We therefore performed genome-wide homozygosity mapping using the HumanCytoSNP-12v2.1 BeadChip (220 K). Several homozygous intervals ranging from 2 to 65 Mb in size were shared between the two affected individuals ([Table 3](#t3){ref-type="table"}). Of the six arCRD causative genes known to date (*ABCA4* \[[@r17]\], *ADAM9* \[[@r18]\], *C8ORF37* \[[@r19]\], *CERKL* \[[@r20]\], *RPGRIP1* \[[@r21]\], and *CDHR1* \[[@r8]\]), *CDHR1* was the only one included in a homozygous interval. Several additional genes known to be involved in other forms of HRD were also located within these intervals, including the following: *GPR98,* underlying Usher syndrome type 2C \[[@r22]\]; *TOPORS*, underlying adRP \[[@r23]\]; and *RGR*, underlying arRP \[[@r24]\]. However, since the phenotype in both patients was consistent with a diagnosis of CRD, *CDHR1* appeared the best candidate gene in this family. Sequence analysis of the 17 coding exons of *CDHR1*, including exon-intron boundaries, was performed in one affected individual. We identified a single base transversion, c.1485+2T\>G, located in the conserved donor splice site of Intron 13 ([Figure 1B](#f1){ref-type="fig"}). This mutation was present homozygously in both affected individuals, and heterozygously in their two unaffected siblings ([Figure 1A](#f1){ref-type="fig"}). The mutation was not detected in the 1000 [Genomes Database](http://browser.1000genomes.org/) or in 208 ethnically-matched control chromosomes, indicating that it is not a common polymorphism. This was done by restriction digest, as described in detail in the Methods section. Our Israeli patients with CRD included ten families of Christian Arab descent. In four families, pathogenic mutations of other HRD-causative genes have been detected. The c.1485+2T\>G mutation of *CDHR1* was not detected in the six remaining families. These findings indicate that c.1485+2T\>G is probably a rare private mutation and does not significantly contribute to the CRD phenotype among Israeli Christian Arabs.

###### Homozygosity mapping results in family TB127

  Chromosome   Interval of homozygosity (Mb)   Interval size (Mb)   Candidate genes
  ------------ ------------------------------- -------------------- -----------------
  9            26--91                          65                   *TOPORS*
  5            82--106                         24                   *GPR98*
  3            133--146                        13                   
  10           83--95                          12                   *CDHR1, RGR*
  7            0--8                            8                    
  10           120--124                        4                    
  3            94--96                          2                    
  8            19--21                          2                    
  16           79--81                          2                    

In silico analysis of the splice site mutation
----------------------------------------------

According to the splice site consensus sequence in mammals, a T nucleotide is located at position +2 of the donor site \[[@r25]\]. Indeed, in the wild-type *CDHR1* allele a T is located at position +2 of intron 13. However, in the mutant allele the nucleotide at position +2 is G ([Figure 1B](#f1){ref-type="fig"}). To predict the effect of this transversion on splicing, we performed in silico analysis of the sequence using two different web-based tools ([Automated Splice Site Analyses](https://splice.uwo.ca/) and ASD -- [Intron Analysis](http://www.ebi.ac.uk/asd-srv/wb.cgi?method=6)). Both algorithms predicted that the c.1485+2T\>G mutation leads to elimination of the Intron 13 donor site ([Table 4](#t4){ref-type="table"} and data not shown).

###### Analysis of CDHR1 intron 13 donor splice-site and adjacent potential sites by the Automated Splice Site Analyses tool

  Genomic coordinate\*   wt sequence   Mutant sequence   Position relative to natural site   Initial score (Ri)†   Final score (Ri)‡   ΔRi║
  ---------------------- ------------- ----------------- ----------------------------------- --------------------- ------------------- ------
  85,970,922--85970923   acagtggg      acaggggg          0                                   4.0                   −4.2                −8.2
  85,970,950--85970951   tgggtggg      NA                +27                                 3.8                   3.8                 0.0

NA, not applicable \*Position of donor site according to human genome reference sequence (hg19) †Initial score measured at the base before the mutation is made ‡ Final score measured at the base after the mutation is made ║Final (Ri)-Initial (Ri)

*CDHR1* cDNA (GenBank accession number [NM_033100.2](http://www.ncbi.nlm.nih.gov/nuccore/NM_033100.2)) encodes for a protein of 859 amino acids, which includes six EC domains, a transmembrane domain, and a unique intracellular domain. The exact effect of the c.1485+2T\>G splicing mutation on *CDHR1* transcripts in vivo is not known. One option is retention of the entire Intron 13, which is expected to yield a protein of 548 amino acids, in which the last 54 amino acids are incorrect. Another option is that elimination of the natural Intron 13 donor splice site leads to the use of a cryptic donor site. Analysis of the *CDHR1* gene with the Automated Splice Site Analyses tool indicated the presence of a relatively strong cryptic donor site located 27 bp downstream of the native splice site within Intron 13 ([Table 4](#t4){ref-type="table"}). The use of this cryptic site is expected to yield a protein of 543 amino acids, in which the last 49 amino acids are incorrect. Both options yield proteins in which two EC domains, the transmembrane domain, and the entire intracellular domain are missing.

Discussion
==========

The aim of the current study was to investigate the genetic basis for arCRD in a consanguineous Israeli Christian Arab family. Genetic analysis revealed a novel splice site mutation of *CDHR1*, c.1485+2T\>G. We performed in silico analysis, which demonstrated that the Intron 13 donor splice site harboring this mutation is not efficiently recognized by the human splicing machinery. Although the exact effect of this splicing mutation on *CDHR1* transcripts in vivo is not known, the expected outcome is incorrect splicing, leading to an abnormal protein product.

The phenotype associated with *CDHR1* mutations reported to date is consistent with a diagnosis of arCRD. In general, clinical findings in affected individuals from family TB127 are similar to those previously reported in patients with other *CDHR1* mutations. These include progressive deterioration of visual acuity, photophobia, defective color vision, loss of central visual fields, macular atrophy, retinal vessel attenuation, and reduced or absent ERG responses. Interestingly, in previously reported cases pigment deposits were predominantly localized to the macular region. This was not seen in our patients. Pigmentary deposits were detected in one patient only and were localized mainly to the peripheral region \[[@r8],[@r12]\] ([Table 2](#t2){ref-type="table"} and [Figure 2](#f2){ref-type="fig"}).

To date, six arCRD causative genes have been identified. In a recent survey of a large CRD cohort from the Netherlands, *ABCA4* mutations were found in 26% of the patients with arCRD \[[@r2]\]. In contrast, mutations in other arCRD genes are rare, and each one is found in only a few families worldwide. For example, only eight mutations have been reported for *CERKL* \[[@r20],[@r26]--[@r30]\], four mutations for *ADAM9* \[[@r18]\], and three mutations for *C8ORF37* \[[@r19]\]. Since a pathogenic *CDHR1* mutation was identified in a family from the Faroe Islands in 2010, only two additional mutations have been reported \[[@r8],[@r12]\] ([Table 1](#t1){ref-type="table"}). This small number suggests that mutations in this gene are a rare cause of arCRD. Here we report a consanguineous Israeli Christian Arab family segregating arCRD due to a novel splice site mutation of *CDHR1*. This report expands the spectrum of pathogenic mutations of the *CDHR1* gene.
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